Literature DB >> 8139609

Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.

J J van Hilten1, A D van der Zwan, A H Zwinderman, R A Roos.   

Abstract

Although the Unified Parkinson's Disease Rating Scale (UPDRS) is widely used to monitor disease progression and drug efficacy, no attempts have been made to evaluate its scientific and clinical quality. Poor clinical sensibility of items in the activities of daily living (ADL) section and redundancy of items in the motor examination (ME) section prompted us to determine if the number of items in these sections could be reduced to a smaller, equally sensitive set that would describe the data as reliably as did the original set of items. Therefore, we assessed 111 patients with idiopathic Parkinson's disease on the UPDRS and Hoehn and Yahr staging scales. Our results show that the ADL (13 items) and ME (14 items) sections can be reduced to 8 items each without loss of reliability or validity. Our report is preliminary and needs validation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139609     DOI: 10.1002/mds.870090113

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Excessive fragmentary myoclonus in patients with Parkinson's disease: prevalence and clinico-polysomnographic profile.

Authors:  Manoel Alves Sobreira-Neto; Márcio Alexandre Pena-Pereira; Emmanuelle Silva Tavares Sobreira; Marcos Hortes Nisihara Chagas; Vitor Tumas; Regina Maria França Fernandes; Alan Luiz Eckeli
Journal:  Sleep Breath       Date:  2015-01-08       Impact factor: 2.816

2.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

3.  Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis.

Authors:  Tatiana Dubayova; Martina Krokavcova; Iveta Nagyova; Jaroslav Rosenberger; Zuzana Gdovinova; Berrie Middel; Johan W Groothoff; Jitse P van Dijk
Journal:  Qual Life Res       Date:  2012-10-11       Impact factor: 4.147

Review 4.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

5.  Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder.

Authors:  B N Dugger; M E Murray; B F Boeve; J E Parisi; E E Benarroch; T J Ferman; D W Dickson
Journal:  Neuropathol Appl Neurobiol       Date:  2012-04       Impact factor: 8.090

6.  Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study.

Authors:  D T Wade; H Gage; C Owen; P Trend; C Grossmith; J Kaye
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

7.  Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease.

Authors:  Tatiana Dubayova; Iveta Nagyova; Eva Havlikova; Jaroslav Rosenberger; Zuzana Gdovinova; Berrie Middel; Jitse P van Dijk; Johan W Groothoff
Journal:  Qual Life Res       Date:  2008-11-07       Impact factor: 4.147

8.  The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.

Authors:  Chadwick W Christine; J William Langston; Robert S Turner; Philip A Starr
Journal:  J Neurosurg       Date:  2009-02       Impact factor: 5.115

9.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Authors:  C W Christine; P A Starr; P S Larson; J L Eberling; W J Jagust; R A Hawkins; H F VanBrocklin; J F Wright; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2009-10-14       Impact factor: 9.910

10.  A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA.

Authors:  J Marinus; M Visser; A M Stiggelbout; J Martin Rabey; P Martínez-Martín; U Bonuccelli; P H Kraus; J J van Hilten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.